Pay in 4 interest-free payments of $7.32 Learn more
Ships within 48 hours · Estimated delivery Oct 7 - Oct 12
In 2022, the FDA further approved Jardiance to reduce the risk of cardiovascular death and hospitalization for heart failure in adults
2022 R&D Spend: Novo Nordisk spent 24.05 billion DKK ($3.40 billion USD) on R&D in 2022, a 35.31 percent increase from the 17.77 billion DKK ($2.83 billion USD) the company spent on R&D in 2021
The growing licensing businessin particular, the Skyrizi product licensed out to and sold by AbbViealso contributed significantly to the positive development of the business
Head-to-Head Comparison The difference is approximately two to three times greater weight loss with semaglutide across all metrics
Retatrutide is a new medication under investigation that can help treat overweight people and type-2 diabetes
